The Protecting Free Vaccines Act of 2025 requires group health plans and health insurers to cover vaccines that ACIP has recommended, with no cost sharing, for plan years beginning on or after enactment and before January 1, 2030. The coverage applies across Medicare Part D, Medicaid, CHIP, and private group or individual plans, and it aligns these programs to a baseline set of ACIP recommendations in effect as of October 25, 2024 (including updates under an approved supplement to a biological product licensed under section 351).
The bill also makes parallel amendments to several federal statutes to codify these coverage requirements.
It includes a narrowly scoped exemption for vaccines administered during the minimum intervals established by existing vaccination schedules and creates a series of conforming amendments to ensure consistency across PHSA, ERISA, and the Internal Revenue Code. Through a sunset-like design, the coverage obligation runs through 2029/2030 depending on the program, after which certain limits or updates would apply.
The bill is designed to make vaccines more affordable and consistently accessible, while tying coverage to ACIP recommendations that are current as of the 2024 baseline and then updated as allowed by the law.
At a Glance
What It Does
Imposes a no-cost-sharing coverage requirement for ACIP-recommended immunizations across federal programs (PHSA, ERISA, and IRC) and private plans, for plan years from enactment through the end of 2029 or early 2030. It also adds conforming amendments to reflect this new standard.
Who It Affects
Group health plans, health insurance issuers, Medicare Part D, Medicaid, and CHIP; benefits for individuals and families enrolled in these programs.
Why It Matters
Creates a unified, no-cost pathway for vaccines guided by ACIP recommendations, reducing out-of-pocket costs and encouraging uptake across public programs and private plans.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a nationwide requirement that vaccines recommended by the Advisory Committee on Immunization Practices (ACIP) be covered by major health coverage streams—Medicare, Medicaid, CHIP, and private group or individual plans—without any cost sharing. It accomplishes this by creating new statutory sections in PHSA, ERISA, and the Internal Revenue Code that mirror in substance the no-cost coverage obligation and apply it to plan years beginning on or after enactment and before January 1, 2030.
The baseline for covered vaccines is ACIP recommendations in effect as of October 25, 2024, including vaccines that were updated after that date under a modified approval path to a biological product licensed under section 351 of the Public Health Service Act. A special rule preserves a reduction or exemption if a vaccine is administered during the minimum interval required by existing vaccination schedules.
To ensure consistent implementation, the bill also makes clerical amendments to the table of contents and adds cross-references to ensure coverage under PHSA, ERISA, and the Internal Revenue Code remains aligned. The package also addresses Medicaid and CHIP, extending the no-cost coverage to vaccines under those programs for the same initial window, and includes provisions to protect and preserve access to vaccines for pregnant individuals and children as vaccines move through regulatory updates.
The overall aim is to guarantee affordability and access to ACIP-recommended vaccines across the major coverage lines through the end of 2029 or early 2030, depending on the program.
The Five Things You Need to Know
The bill creates three new federal code sections (PHSA 2799A–11, ERISA 726, and IRC 9826) to codify no-cost vaccine coverage.
Coverage applies to Medicare Part D, Medicaid, CHIP, and private group/individual plans for ACIP-recommended vaccines as of Oct 25, 2024, including later updates.
A special rule exempts vaccines administered during the minimum interval from coverage requirements.
The bill makes parallel amendments to PHSA, ERISA, and the IRC to synchronize benefits across programs.
Some provisions tie coverage to a 2029/2030 sunset timeline and include transitional rules for vaccine lists and revocations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
PHSA: Coverage of ACIP immunizations
Adds a new section 2799A–11 to Part D of title XXVII of the Public Health Service Act. For plan years starting on or after enactment through January 1, 2030, group health plans and health insurance issuers must provide coverage for ACIP-recommended immunizations that were in effect as of October 25, 2024, including vaccines updated after that date via an approved supplemental application to a licensed biological product. Cost sharing is not allowed for these immunizations.
ERISA: Coverage of ACIP immunizations
Adds new section 726 to Subpart B of Part 7 of Subtitle B of Title I of ERISA. For plan years beginning on or after enactment and before January 1, 2030, group health plans and health insurers must provide coverage with no cost sharing for ACIP-recommended vaccines, consistent with the PHSA provision and including updates to vaccines that rely on a 351 license pathway.
IRC: Coverage of ACIP immunizations
Adds new section 9826 to Subchapter B of Chapter 100 of the Internal Revenue Code. For the same effective window, group health plans must cover the vaccines with no cost sharing, including vaccines updated under a supplemental application to a 351 license. The rule mirrors PHSA and ERISA to ensure federal tax-advantaged plans align with national vaccine coverage goals.
Special rule: minimum interval exemption
A non-applicability provision: subsection (a)’s no-cost coverage does not apply to an immunization administered during the minimum interval established under section 2713(b) of the PHSA. This preserves existing timing restrictions where vaccines are not eligible under the new no-cost rule.
Medicare: vaccine coverage and updates
Section 1860D–2(b)(8)(B) of the Social Security Act is amended to require coverage for vaccines with ACIP recommendations that remain in effect and to add a reference to updated recommendations under the 351 pathway, including scenarios where the prior recommendation was revoked after October 25, 2024. The change ensures Medicare Part D plans align with ACIP guidance through the 2030 window.
Medicaid: expanded vaccine coverage
Section 1905(a)(13) and related provisions expand Medicaid to cover vaccines that ACIP recommended as of October 25, 2024, including updated vaccines under 351 licensing, through December 31, 2029 for pediatric vaccines and related provisions for adult vaccines under state plans, subject to the new no-cost-sharing standard.
CHIP: vaccine coverage for children
Section 2103(c)(13) requires CHIP to include vaccines and administration of vaccines that ACIP recommended as of October 25, 2024, with updates under 351 licensing, through December 31, 2029, consistent with the no-cost-sharing obligation and the schedule constraints established by the bill.
State flexibility in benefit design
Section 1937(b)(9) adds a provision allowing states to ensure that adult vaccine coverage remains comprehensive, noting that coverage must include vaccines described in section 1905(a)(13)(B) and that cost sharing for such vaccines is prohibited, preserving uniform access while allowing for state-specific plan design within federal guardrails.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicare beneficiaries and Part D enrollees gain no-cost access to vaccines that ACIP recommends (including updates) without additional out-of-pocket costs.
- Medicaid and CHIP enrollees—particularly low-income children and pregnant individuals—receive expanded, no-cost vaccine coverage as ACIP guidance evolves.
- Individuals and families covered by group health plans and private insurers benefit from predictable, no-cost vaccination costs across many plans.
- Healthcare providers and clinics gain clearer reimbursement pathways and reduced administrative friction when vaccines are covered uniformly across programs.
Who Bears the Cost
- Insurers and employers offering group plans bear the administrative burden of implementing the new coverage without cost sharing, including processing ACIP-based vaccine benefits.
- Public programs (Medicare/Medicaid) may incur higher short-term costs due to expanded vaccine coverage, though intended to reduce longer-term vaccine-prevention costs.
- States face administrative and fiscal adjustments to align with the new federal baseline in CHIP and Medicaid, including potential changes to state plan documents and budgets.
- Pharmaceutical and biologics suppliers may experience shifts in demand patterns as ACIP-based vaccination schedules are updated and expanded.
Key Issues
The Core Tension
A central dilemma is whether guaranteeing no-cost coverage for ACIP-recommended vaccines through 2029/2030 should take precedence over ongoing adaptability to evolving vaccine science and budgetary constraints. This frames the push for uniform federal coverage against the risk of insuring outdated or late-updated vaccine lists, while balancing patient access with programmatic and administrative realities across PHSA, ERISA, and the IRC.
The bill creates a broad coverage mandate tied to ACIP recommendations across multiple programs, but the exact scope of vaccines covered hinges on the ACIP list as of October 25, 2024 and subsequent updates under a Federal licensing path. The interplay between PHSA, ERISA, and the IRC is designed to harmonize coverage, yet creates complexity in administration and cost accounting across diverse plan types.
The sunset-like end date (through 2029 or early 2030, depending on the program) introduces a policy window that may incentivize rapid uptake but also raises questions about future funding, updates, and potential gaps if ACIP recommendations change after the cut-off. The exemption for vaccines administered during minimum intervals also creates a narrow carve-out that could affect some vaccination timing strategies and plan designs.
Finally, state flexibility is constrained by aligning adult vaccine coverage with a uniform federal standard, which could limit some state experimentation with benefit design.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.